Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- Policy Veterans’ Group Renews Call for Company-Proposed Pricing, Floats Support System for Biosimilars
November 15, 2023
- PhRMA Chief Presses Japan to Cut LLP Spending, Shift Funds towards Innovation
November 15, 2023
- PhRMA Chair Urges Japan to Maintain On-Patent Drug Prices, Improve Initial Pricing
November 10, 2023
- Diabetes Groups Urge Govt to Build Stable Supply System for GLP-1s, Other Meds
November 8, 2023
- Chuikyo Rep Interview 4 - JMA Rep Says Any Reform Must Ensure Access to Appropriate Healthcare
November 6, 2023
- GHIT Fund, MPP to Bolster Ties to Enhance Drug Access
October 31, 2023
- 70% of Younger Wholesaler Staffers Ponder Quitting Jobs amid Supply Crunch: Poll
October 30, 2023
- Shipments Curbed or Suspended for 22.9% of Products in September: FPMAJ
October 27, 2023
- Japan Needs New Rule to Price Drugs on Par with US, Europe: JPMA Director
October 27, 2023
- JMA to Seek Wage Hike of “at Least 3%” in 2024 Revision: President
October 27, 2023
- Chuikyo Rep Interview 3-2 - Rengo Wants Substantive Discussions on Pricing System, Off-Year Revisions over Next Few Years
October 26, 2023
- Off-Label Use of GLP-1 Goes against Medical Ethics: JMA Executive
October 26, 2023
- Chuikyo Rep Interview 3-1 - Rengo Seeks Patient-Centric Debate, Sees Exhausted Wholesalers as Big Issue
October 25, 2023
- Neurology Society, SMA Group Urge Nationwide Newborn Test at Public Expense
October 20, 2023
- No Info Received from Member Firms on Impact of Middle East Crisis: JPMA
October 20, 2023
- JGA Vows Cooperation after Generic Panel’s Interim Report
October 20, 2023
- JPMA Renews Call for Abolishing PMP Company Criteria
October 20, 2023
- Group of Academia-Originating Biotechs Boots Up in Japan
October 18, 2023
- Introduce Societal Value Premium for Regenerative Medicine Products: Consultant
October 17, 2023
- Chuikyo Rep Interview 2-3 - With 80% Generic Share, Now Is the Time to Revisit LLP Copay, Says Payer Rep
October 13, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…